RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flow The differentiated mechanism of a dual-targeted ABCB4/BSEP PFM ...

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate ...

One of the quirks about drug hunting is that finding new medicines doesn’t always mean uncovering something completely new. Sometimes it’s about revisiting previously hunted grounds and spotting ...

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of mechanism in non-human primates RTY-406 is in Phase 1 ...

Rectify Pharma calls its new lead candidate a "pipeline-in-a-pill" because of its potential to treat the underlying cause of multiple liver diseases. (iStock / Getty Images Plus) Rectify Pharma is ...

Rectify Pharmaceuticals has launched with $100 million in series A financing to develop drugs that restore the function of ATP-binding cassette (ABC) transporters. ABC transporters are membrane-bound ...

“These translational results demonstrate that Rectify’s PFM reduces vascular calcification and kidney injury and improves kidney function through enhancement of ABCC6 function,” said Rajesh Devraj, Ph ...

BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and ...